[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616834":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":46,"collaborators":48,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":65,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"The Netherlands Cancer Institute","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Intra-operative Sonazoid injection",null,[12],"Drug: Sonazoid",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Sonazoid","Intradermal injection of the ultrasound contrast agent Sonazoid.",[9],[20],{"name":21,"affiliation":5,"role":22},"Quirijn Tummers","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Marijn Hiep","CONTACT","+31205121751","ma.hiep@nki.nl",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Netherlands Cancer Institute","RECRUITING","Amsterdam","North Holland","1066 CX","Netherlands","NL",{"type":39,"coordinates":40},"Point",[41,42],4.88969,52.37403,{"lat":42,"lon":41},[45],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[49],{"name":50,"class":51},"GE Healthcare","INDUSTRY","100616834","phase-2-contrast-enhanced-ultrasound-for-sentinel-node-detection-100616834",false,"NCT07310758","Contrast-enhanced Ultrasound for Sentinel Node Detection","Contrast-enhanced Ultrasound for Sentinel Node Detection in Patients With Melanoma, Breast Cancer or Head & Neck Cancer","Inclusion Criteria:\n\n* Aged 18 years or older\n* Patient has been diagnosed with cancer in the skin (melanoma), breast or head \\& neck (including melanoma of head and neck area)\n* In case of a melanoma: it should be located in the limbs or head and neck area\n* Scheduled for a surgical SN procedure at the NKI-AvL\n* Patient provides written informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Any known clinically significant acute hypersensitivity reaction to the study medication, such as eggs or egg products\n* Other contra-indications for Sonazoid contrast agent, including arteriovenous cardiac or pulmonary shunt, serious coronary arterial disease and serious pulmonary disease","ALL","18 Years",{"count":62,"type":63},91,"ESTIMATED","INTERVENTIONAL",[66,67],"PHASE2","PHASE3","This is a prospective single-center interventional non-inferiority study where subjects are participating for one day for patients 18 years or older with melanoma, breast cancer or head \\& neck cancer (including melanoma of head and neck area) and scheduled for a surgical SN procedure in the NKI-AvL without any contra-indication for Sonazoid contrast agent, such as an allergy to eggs or egg products. The primary objective is to assess the sensitivity of CEUS for intra-operative SN localization compared to the gold standard (99mTc nanocolloid). Secondary objectives are the specificity of CEUS for intra-operative SN localization, the time required to localize the SNs using CEUS and intraoperative usability of the CEUS-system. The primary endpoint is the sensitivity of the CEUS SN localization method. The conventional gamma probe will be used as ground truth comparison.",[70,71,72],"Melanoma","Breast Cancer","Head & Neck Cancer",[74],"contrast-enhanced ultrasound","2025-12-16",{"date":77,"type":78},"2025-12-30","ACTUAL",{"date":80,"type":78},"2025-09-18",{"date":82,"type":63},"2026-09-18",{"name":5,"class":6},1]